Sur Daniel, Havasi Andrei, Cainap Calin, Samasca Gabriel, Burz Claudia, Balacescu Ovidiu, Lupan Iulia, Deleanu Diana
11th Department of Medical Oncology, University of Medicine and Pharmacy "Iuliu Hatieganu", 400015 Cluj-Napoca, Romania.
Department of Medical Oncology, The Oncology Institute "Prof. Dr. Ion Chiricuta", 400015 Cluj-Napoca, Romania.
J Clin Med. 2020 Jan 9;9(1):182. doi: 10.3390/jcm9010182.
Chimeric antigen receptor (CAR) T-cell therapy represents a new genetically engineered method of immunotherapy for cancer. The patient's T-cells are modified to express a specific receptor that sticks to the tumor antigen. This modified cell is then reintroduced into the patient's body to fight the resilient cancer cells. After exhibiting positive results in hematological malignancies, this therapy is being proposed for solid tumors like colorectal cancer. The clinical data of CAR T-cell therapy in colorectal cancer is rather scarce. In this review, we summarize the current state of knowledge, challenges, and future perspectives of CAR T-cell therapy in colorectal cancer. A total of 22 articles were included in this review. Eligible studies were selected and reviewed by two researchers from 49 articles found on Pubmed, Web of Science, and clinicaltrials.gov. This therapy, at the moment, provides modest benefits in solid tumors. Not taking into consideration the high manufacturing and retail prices, there are still limitations like increased toxicities, relapses, and unfavorable tumor microenvironment for CAR T-cell therapy in colorectal cancer.
嵌合抗原受体（CAR）T细胞疗法是一种新型的癌症基因工程免疫疗法。患者的T细胞经过改造，以表达一种能附着于肿瘤抗原的特异性受体。然后，这种经过改造的细胞被重新引入患者体内，以对抗顽强的癌细胞。在血液系统恶性肿瘤中显示出积极效果后，这种疗法正被应用于结直肠癌等实体瘤。CAR T细胞疗法在结直肠癌中的临床数据相当匮乏。在本综述中，我们总结了CAR T细胞疗法在结直肠癌中的当前知识状态、挑战和未来前景。本综述共纳入22篇文章。两名研究人员从在PubMed、科学网和ClinicalTrials.gov上找到的49篇文章中筛选并评审了符合条件的研究。目前，这种疗法在实体瘤中提供的益处有限。不考虑高昂的生产成本和零售价，CAR T细胞疗法在结直肠癌中仍存在一些局限性，如毒性增加、复发以及不利的肿瘤微环境。
